stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) Return on invested capital
Neogen Corporation's return on invested capital over the twelve months to 31 August 2026 was −0.17%, up 0.3 percentage points from fiscal 2026 (−0.50%). Over the past ten years it has ranged from −23.4% (fiscal 2025) to 14.0% (fiscal 2015); the current reading is higher than 17% of that period. That is above the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | −0.50% | 22.88 |
| FY2025 | −23.4% | (24.33) |
| FY2024 | 0.95% | 0.33 |
| FY2023 | 0.62% | (6.60) |
| FY2022 | 7.22% | (2.85) |
| FY2021 | 10.1% | (0.96) |
| FY2020 | 11.0% | (0.46) |
| FY2019 | 11.5% | (1.07) |
| FY2018 | 12.6% | 0.19 |
| FY2017 | 12.4% | 0.48 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| TMDX TransMedics Group, Inc. compare | 48.0% |
| UFPT UFP Technologies, Inc. compare | 11.2% |
| ITGR Integer Holdings Corporation compare | 3.16% |
| INSP Inspire Medical Systems, Inc. compare | 1.97% |
| NEOG Neogen Corporation | −0.17% |
| AXGN AxoGen, Inc. compare | −5.27% |
| ESTA Establishment Labs Holdings Inc. compare | −5.53% |
| ALMR Alamar Biosciences, Inc. compare | −10.1% |
| BFLY Butterfly Network, Inc. compare | −58.2% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on NEOG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement